1. Home
  2. SENS vs EOLS Comparison

SENS vs EOLS Comparison

Compare SENS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$7.97

Market Cap

476.9M

Sector

Industrials

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$7.28

Market Cap

500.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENS
EOLS
Founded
1996
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
476.9M
500.0M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
SENS
EOLS
Price
$7.97
$7.28
Analyst Decision
Buy
Buy
Analyst Count
8
6
Target Price
$13.67
★ $15.00
AVG Volume (30 Days)
621.9K
★ 622.8K
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1.23
EPS
N/A
★ N/A
Revenue
$16,389,000.00
★ $297,176,000.00
Revenue This Year
$82.21
$12.44
Revenue Next Year
$55.63
$17.37
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 19.85
11.61
52 Week Low
$4.79
$3.86
52 Week High
$10.64
$9.31

Technical Indicators

Market Signals
Indicator
SENS
EOLS
Relative Strength Index (RSI) 34.55 41.13
Support Level $7.35 $7.07
Resistance Level $8.49 $7.28
Average True Range (ATR) 0.47 0.32
MACD -0.27 -0.05
Stochastic Oscillator 4.33 17.62

Price Performance

Historical Comparison
SENS
EOLS

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: